Investor Ideas Potcasts #Cannabis News and Stocks on the Move: TSX: $APHA.TO, NYSE: $APHA, CSE: $KBEV.C, TSXV: $KHRN.V
Delta, Kelowna, BC - November 8, 2018 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today's edition of its series, Investorideas.com potcastsCM - cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Investor Ideas Potcasts #Cannabis News and Stocks on the Move: TSX: $APHA.TO, NYSE: $APHA, CSE: $KBEV.C, TSXV: $KHRN.V
Hear Investor ideas cannabis potcast on iTunes
Today's podcast overview/transcript:
Good afternoon and welcome to another Investorideas.com Potcast - following Cannabis news, stocks to watch as well as insights from thought leaders and experts.
Today we will be looking at announcements from Aphria Inc. Trading on the TSX and NYSE as APHA, Koios Beverage Corp. trading on the CSE as KBEV and Khiron Life Sciences Corp. trading on the TSX-Venture as KHRN.
But first, according to a new report from New Frontier Data, the authority in data, analytics and business intelligence on the global cannabis industry, the legalization of medical cannabis in Utah and Missouri and legalization of adult-use in Michigan will result in new markets that are projected to account for more than $1.2 billion in additional sales for a combined total of $2.1 billion in total legal sales by 2025. This increase will create more than 30,000 additional cannabis jobs over the same period.
"Cannabis legalization in some form has occurred in nearly 60% of the United States, and based on our research, legal retail sales revenues are currently estimated to be $10.3 billion in 2018; we now project the market to grow to more than $25 billion while supporting more than 642,000 jobs by 2025," said Giadha Aguirre de Carcer, Founder and CEO of New Frontier Data.
The revised projections take into consideration the outcome of four state ballot initiatives:
Michigan passed Proposal 1, legalizing recreational use and making Michigan the fifth largest legal U.S. cannabis market; combined with medical, annual sales are projected to reach $1.9 billion in total legal sales by 2025.
Missouri passed Amendment 2, legalizing state-wide medical cannabis; resulting annual retail sales are projected to reach $111 million by 2025.
Utah voters passed Proposition 2, legalizing medical cannabis; annual retail sales are projected to reach $63 million by 2025.
North Dakota voted down Measure 3, which would have allowed adults to grow, consume and possess as much cannabis as they want, without government oversight and without state taxation; annual recreational sales could have reached $67.5 million by 2025.
Aphria Inc. announced its proposed acquisition of CC Pharma GmbH, a leading distributor of pharmaceutical products to more than 13,000 pharmacies in Germany. The transaction, when closed, will strengthen the Company's end-to-end medical cannabis operations and infrastructure in Germany, a key market in Aphria's international expansion. It is anticipated that the transaction will close in January 2019.
"This acquisition strengthens our foothold in Germany, one of the most highly sought-after medical cannabis markets in the world," said Vic Neufeld, CEO of Aphria. "CC Pharma is cash-flow positive and has significant experience with regulatory requirements and international logistics. It will be a strong addition to Aphria's presence in Germany, providing deeper access to the important pharmacist channel and advancing our ambitious global growth strategy."
Founded in 1999, CC Pharma is a leading importer and distributor of EU-pharmaceuticals for the German market, with over €200 million in annual revenue. Aphria, through its subsidiary Aphria International, previously announced a supply agreement with CC Pharma to export approximately 1,200 kilograms of medical cannabis products from Canada to Germany. With Aphria's experience as a global cannabis leader, the Company will create a new division of CC Pharma dedicated to medical cannabis. CC Pharma operates a production, repackaging and labeling facility at its headquarters in Densborn.
Koios Beverage Corp. announced that the Company will be initiating a clinical study into the impact of CBD on the human brain.
Koios is already conducting a clinical trial on the impact of its nootropic supplements on the human brain, and released preliminary results on Oct. 9, 2018. Koios beverages and supplements contain a proprietary formula of nootropic, brain-enhancing nutrients.
The trial involved mapping the activity of the brain before and after subjects consumed Koios nootropic supplements.
Full clinical brain scans on Koios users show changes in brain activity in three main areas, all of which indicate improved cognitive function.
"The findings, although preliminary, are better than we could have expected," said Chris Miller, CEO of the Company. "Changes in the type of brain activity that we are seeing between the baseline that was mapped at the start of the study, and the effect on participants after several months of consuming our beverages, could have many positive implications."
Vice President of Sales Gina Burrus says the results are helping the Company in the design of future products, and so Koios has decided to launch similar trials of nootropics with CBD.
"It's long been known that CBD can have a dramatic impact on the human brain, all the way from helping people relax to treating people for epilepsy," said Burrus. "However, we don't yet know what impact CBD will have when combined with nootropics, and that's what this study is designed to tell us."
Both studies are being conducted by NeuraPerformance/Neuroptimize Brain Center, the go-to brain lab and physiotherapy clinic for Colorado's elite athletes, including the Denver Broncos football team. The lab's brain-mapping technique involves using sensors to measure the electrical activity within the client's brain.
NeuraPerformance/Neuroptimize is expected to release a full report within the next month, after which it will begin further testing of nootropics and CBDs.
Khiron Life Sciences Corp., an integrated medical cannabis company with its core operations in Colombia, welcomed the initiative presented yesterday by the incoming Government of Mexico through its next secretary of the Interior, Dr. Olga Sánchez Cordero, for the Regulation and Control of Cannabis in Mexico.
The General Law for the Regulation and Control of Cannabis, presented by Dr. Olga Sanchez will establish Mexico among Latin American countries that have legislated the use of cannabis for recreational, medical, scientific, research, industrial and commercial purposes. Mexico has the second largest population in Latin America and 11.7 million potential patients for medical cannabis. (source: IMS Quintiles 2017). The new legislation will develop in more detail the conditions for recreational cannabis use already authorized by judicial decisions, and also define final details for medical use.
Alvaro Torres, Co-founder and CEO for Khiron stated, "Khiron is a leader in the medical cannabis sector in Latin America working with all levels of government, health professionals and patients to establish a safe and regulated cannabis environment. We welcome the presentation made yesterday by the next secretary of Interior, Dr. Olga Sánchez Cordero, and we look forward to the opportunity to work with the administration to develop a strong and successful cannabis industry in Mexico."
Former Mexican President and Khiron board member Mr. Vicente Fox stated, "As a Latin America focused company, Khiron is positioned to maximize the legislation proposed yesterday and to bring the benefits of a legalized cannabis environment to all Mexicans, which has the potential to reduce crime, increase prosperity and improve the health of our citizens."
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Subscribe to the new cannabis podcast series:
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
Get the cannabis/hemp stock directory as an Investor ideas member, plus get weekly updates with new pot stocks added and get the daily potcast for Investor Ideas #Potcasts #Cannabis News and Stocks on the Move. Learn more https://www.investorideas.com/membership/
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and sector trends from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto, technology including AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts#Cannabis News and Stocks on the Move podcast and column and the Cleantech and Climate Change Podcast.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp. Learn more about Investor ideas podcast and news publication services and costs https://www.investorideas.com/News-Upload/
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: https://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
